目的探讨心力衰竭患者血浆补体C1q肿瘤坏死因子相关蛋白3(C1q tumor necrosis factor related proteins-3,CTRP3)、血管生成素样蛋白2(angiopoietin like protein 2,angptl2)、可溶性致癌抑制因子2(soluble suppression of tumorigenici...目的探讨心力衰竭患者血浆补体C1q肿瘤坏死因子相关蛋白3(C1q tumor necrosis factor related proteins-3,CTRP3)、血管生成素样蛋白2(angiopoietin like protein 2,angptl2)、可溶性致癌抑制因子2(soluble suppression of tumorigenicity 2,sST2)的浓度及预后价值。方法选择2014年8月到2018年2月在北京市垂杨柳医院心内科收治的心力衰竭患者122例作为心力衰竭组,并分为收缩性心力衰竭组62例和舒张性心力衰竭组60例两个亚组;对照组为非心力衰竭人群122例。采用酶联免疫吸附法检测混杂血浆CTRP3、angptl2、sST2浓度,随访调查患者的预后并进行相关性分析与预测价值分析。结果心力衰竭组的左心室射血分数(left ventricular ejection fraction,LVEF)低于对照组,左心室舒张末期内径(left ventricular end diastolic dimension,LVEDD)及血尿素、肌酐浓度高于对照组,差异有统计学意义(P<0.05)。两组总胆固醇、低密度脂蛋白胆固醇浓度比较,差异无统计学意义(P>0.05)。两亚组心功能与生化指标比较,差异无统计学意义(P>0.05)。心力衰竭组的血浆angptl2、sST2浓度高于对照组,CTRP3浓度低于对照组,差异有统计学意义(P<0.05);两亚组CTRP3、angptl2、s ST2浓度比较,差异无统计学意义(P>0.05)。随访至今,心力衰竭组患者中预后不良16例,发生率为13.1%。Pearson相关分析结果显示CTRP3、angptl2、sST2、LVEF、LVEDD、尿素、肌酐都与心力衰竭患者预后显著相关(P<0.05)。Cox回归模型分析显示CTRP3、angptl2、sST2为影响心力衰竭患者预后的主要因素(P<0.05)。结论心力衰竭患者血清CTRP3、angptl2、sST2浓度呈现异常表达情况,具有预测预后不良的价值,是心力衰竭预后评估的生物学标志物。展开更多
目的:克隆血管生成素样蛋白2(angiopoietin like protein2,ANGPTL2)cDNA;构建ANGPTL2纤维蛋白原样功能域原核表达载体;表达得到ANGPTL2纤维蛋白原样功能域融合蛋白;制备针对ANGPTL2纤维蛋白原样功能域的多克隆抗体,为全面分析研究ANGPTL...目的:克隆血管生成素样蛋白2(angiopoietin like protein2,ANGPTL2)cDNA;构建ANGPTL2纤维蛋白原样功能域原核表达载体;表达得到ANGPTL2纤维蛋白原样功能域融合蛋白;制备针对ANGPTL2纤维蛋白原样功能域的多克隆抗体,为全面分析研究ANGPTL2的功能及其与糖尿病肾病微血管病变的关系创造条件。方法:利用RT-PCR方法从肾脏总RNA中扩增ANGPTL2全长cDNA;以其为模板扩增编码ANGPTL2纤维蛋白原样功能域的cDNA片段,并进而将其克隆至原核表达载体pET-15b上,构建成ANGPTL2纤维蛋白原样功能域的原核表达载体pET-ANGPTL2;将pET-ANGPTL2导入BL21(DE3)菌内,通过IPTG诱导表达重组蛋白;利用重组蛋白5'端带有Histag的特点,采用含Ni的树脂进行亲和吸附纯化,获取高纯度的重组蛋白;将重组蛋白免疫新西兰大白兔,制备兔抗ANGPTL2多克隆抗体;利用ELISA法测定和免疫组化分析对此多抗的效价和特异性进行分析。结果:取得了带有完整阅读框的ANGPTL2全长cDNA;构建成与预先设计完全一致的原核表达载体pET-ANGPTL2;成功地在大肠杆菌中进行了ANGPTL2纤维蛋白原样功能域融合蛋白的表达,纯化获取纯度很高的重组蛋白;经免疫兔获取高效价的针对ANGPTL2纤维蛋白原样功能域的多克隆抗体;ELISA检测和免疫组化分析表明,此抗体不仅具有很高的效价,而且具有很好的特异性。结论:我们成功地克隆了ANGPTL2cDNA,构建了其原核表达载体,进行了原核表达,成功取得高纯度的重组蛋白,并得到了高效价、高特异性针对ANGPTL2纤维蛋白原样功能域的多克隆抗体,为全面分析研究ANGPTL2功能及其与糖尿病肾病微血管病变的关系创造条件。展开更多
Background：A recent study reported a positive association between elevated serum levels of angiopoietin-like protein 2 （ANGPTL2） and the development of type 2 diabetes in a general population.However,the relationsh...Background：A recent study reported a positive association between elevated serum levels of angiopoietin-like protein 2 （ANGPTL2） and the development of type 2 diabetes in a general population.However,the relationship of serum ANGPTL2 levels with the risk of developing gestational diabetes mellitus （GDM） has not been reported to date.The aim of this study was to investigate the change of maternal serum ANGPTL2 concentrations in the first trimester of pregnancy and to determine whether ANGPTL2 is a biomarker for subsequent GDM development.Methods：We conducted a prospective,nested case-control study in a pregnancy cohort.First-trimester ANGPTL2 levels were measured using a high-resolution assay in 89 women who subsequently developed GDM and in a random sample of 177 women who remained euglycemic throughout the pregnancy.Median ANGPTL2 levels were compared using Mann-Whitney U-test.Logistic regression was used to compute unadjusted and multivariable-adjusted odds ratios for developing GDM among ANGPTL2 quartiles.Results：The serum levels of ANGPTL2 was higher in women with GDM than that in women without GDM （3.06 [2.59,3.65] ng/ml vs.2.46 [2.05,2.96] ng/ml,P =0.003）.Fasting blood glucose was higher in women with GDM than that in women without GDM （5.0 ± 0.9 mmol/L vs.4.4 ± 0.6 mmol/L,P 〈 0.001）.Glucose challenge test showed that the blood glucose was higher in women with GDM than that in women without GDM （9.1 ± 3.5 mmol/L vs.6.2 ± 1.2 mmol/L,P 〈 0.001）.A multivariate model adjusted for baseline characteristics,medical complications,and gestational characteristics revealed that the risk of developing GDM among women in Q4 compared with Q1 was 2.90-fold more likely to develop GDM later in pregnancy.Conclusions：At 1 1-13 weeks in pregnancies that develop GDM,the serum concentration of ANGPTL2 is increased,and it can be combined with maternal factors to provide effective early screening for GDM.展开更多
文摘目的探讨心力衰竭患者血浆补体C1q肿瘤坏死因子相关蛋白3(C1q tumor necrosis factor related proteins-3,CTRP3)、血管生成素样蛋白2(angiopoietin like protein 2,angptl2)、可溶性致癌抑制因子2(soluble suppression of tumorigenicity 2,sST2)的浓度及预后价值。方法选择2014年8月到2018年2月在北京市垂杨柳医院心内科收治的心力衰竭患者122例作为心力衰竭组,并分为收缩性心力衰竭组62例和舒张性心力衰竭组60例两个亚组;对照组为非心力衰竭人群122例。采用酶联免疫吸附法检测混杂血浆CTRP3、angptl2、sST2浓度,随访调查患者的预后并进行相关性分析与预测价值分析。结果心力衰竭组的左心室射血分数(left ventricular ejection fraction,LVEF)低于对照组,左心室舒张末期内径(left ventricular end diastolic dimension,LVEDD)及血尿素、肌酐浓度高于对照组,差异有统计学意义(P<0.05)。两组总胆固醇、低密度脂蛋白胆固醇浓度比较,差异无统计学意义(P>0.05)。两亚组心功能与生化指标比较,差异无统计学意义(P>0.05)。心力衰竭组的血浆angptl2、sST2浓度高于对照组,CTRP3浓度低于对照组,差异有统计学意义(P<0.05);两亚组CTRP3、angptl2、s ST2浓度比较,差异无统计学意义(P>0.05)。随访至今,心力衰竭组患者中预后不良16例,发生率为13.1%。Pearson相关分析结果显示CTRP3、angptl2、sST2、LVEF、LVEDD、尿素、肌酐都与心力衰竭患者预后显著相关(P<0.05)。Cox回归模型分析显示CTRP3、angptl2、sST2为影响心力衰竭患者预后的主要因素(P<0.05)。结论心力衰竭患者血清CTRP3、angptl2、sST2浓度呈现异常表达情况,具有预测预后不良的价值,是心力衰竭预后评估的生物学标志物。
文摘目的:克隆血管生成素样蛋白2(angiopoietin like protein2,ANGPTL2)cDNA;构建ANGPTL2纤维蛋白原样功能域原核表达载体;表达得到ANGPTL2纤维蛋白原样功能域融合蛋白;制备针对ANGPTL2纤维蛋白原样功能域的多克隆抗体,为全面分析研究ANGPTL2的功能及其与糖尿病肾病微血管病变的关系创造条件。方法:利用RT-PCR方法从肾脏总RNA中扩增ANGPTL2全长cDNA;以其为模板扩增编码ANGPTL2纤维蛋白原样功能域的cDNA片段,并进而将其克隆至原核表达载体pET-15b上,构建成ANGPTL2纤维蛋白原样功能域的原核表达载体pET-ANGPTL2;将pET-ANGPTL2导入BL21(DE3)菌内,通过IPTG诱导表达重组蛋白;利用重组蛋白5'端带有Histag的特点,采用含Ni的树脂进行亲和吸附纯化,获取高纯度的重组蛋白;将重组蛋白免疫新西兰大白兔,制备兔抗ANGPTL2多克隆抗体;利用ELISA法测定和免疫组化分析对此多抗的效价和特异性进行分析。结果:取得了带有完整阅读框的ANGPTL2全长cDNA;构建成与预先设计完全一致的原核表达载体pET-ANGPTL2;成功地在大肠杆菌中进行了ANGPTL2纤维蛋白原样功能域融合蛋白的表达,纯化获取纯度很高的重组蛋白;经免疫兔获取高效价的针对ANGPTL2纤维蛋白原样功能域的多克隆抗体;ELISA检测和免疫组化分析表明,此抗体不仅具有很高的效价,而且具有很好的特异性。结论:我们成功地克隆了ANGPTL2cDNA,构建了其原核表达载体,进行了原核表达,成功取得高纯度的重组蛋白,并得到了高效价、高特异性针对ANGPTL2纤维蛋白原样功能域的多克隆抗体,为全面分析研究ANGPTL2功能及其与糖尿病肾病微血管病变的关系创造条件。
基金This study was supported by the grant of the National Natural Science Foundation of China （No. 81471427）.
文摘Background：A recent study reported a positive association between elevated serum levels of angiopoietin-like protein 2 （ANGPTL2） and the development of type 2 diabetes in a general population.However,the relationship of serum ANGPTL2 levels with the risk of developing gestational diabetes mellitus （GDM） has not been reported to date.The aim of this study was to investigate the change of maternal serum ANGPTL2 concentrations in the first trimester of pregnancy and to determine whether ANGPTL2 is a biomarker for subsequent GDM development.Methods：We conducted a prospective,nested case-control study in a pregnancy cohort.First-trimester ANGPTL2 levels were measured using a high-resolution assay in 89 women who subsequently developed GDM and in a random sample of 177 women who remained euglycemic throughout the pregnancy.Median ANGPTL2 levels were compared using Mann-Whitney U-test.Logistic regression was used to compute unadjusted and multivariable-adjusted odds ratios for developing GDM among ANGPTL2 quartiles.Results：The serum levels of ANGPTL2 was higher in women with GDM than that in women without GDM （3.06 [2.59,3.65] ng/ml vs.2.46 [2.05,2.96] ng/ml,P =0.003）.Fasting blood glucose was higher in women with GDM than that in women without GDM （5.0 ± 0.9 mmol/L vs.4.4 ± 0.6 mmol/L,P 〈 0.001）.Glucose challenge test showed that the blood glucose was higher in women with GDM than that in women without GDM （9.1 ± 3.5 mmol/L vs.6.2 ± 1.2 mmol/L,P 〈 0.001）.A multivariate model adjusted for baseline characteristics,medical complications,and gestational characteristics revealed that the risk of developing GDM among women in Q4 compared with Q1 was 2.90-fold more likely to develop GDM later in pregnancy.Conclusions：At 1 1-13 weeks in pregnancies that develop GDM,the serum concentration of ANGPTL2 is increased,and it can be combined with maternal factors to provide effective early screening for GDM.
